TRIP13 and primary cutaneous T-cell non-Hodgkin lymphoma: High TRIP13 expression has been identified in multiple cancers, including prostate cancer [19], primary cutaneous T-cell lymphoma [20], non-small cell lung cancer [21], and breast cancer [22].